Wakefit Innovations IPO Overview (as on 3-Dec-2025)
| Detail | Info |
|---|---|
| IPO Open Date | 8 December 2025 Investor Gain+2mint+2 |
| IPO Closing Date | 10 December 2025 Investor Gain+1 |
| Price Band | ₹185 – ₹195 per share mint+2Investor Gain+2 |
| Face Value | ₹1 per share Investor Gain+1 |
| Issue Size | ~ ₹1,288.89 crore Investor Gain+1 |
| Fresh Issue | ~ ₹377.18 crore Investor Gain+1 |
| Offer-for-Sale (OFS) | ~ ₹911-912 crore Investor Gain+1 |
| Minimum Lot (Retail) | 76 shares (≈ ₹14,820 at ₹195) Investor Gain+1 |
| Listing On | BSE & NSE Investor Gain+1 |
Business & Financial Background — What’s Wakefit All About
- Wakefit is a Bengaluru-based Direct-to-Consumer (D2C) company offering home and sleep solutions — mattresses, furniture, home décor. Equitymaster+2IPO Central+2
- As of recent filings, Wakefit operates through a mix of online + offline channels: it has company-owned stores (COCO) and a presence in multi-brand outlets across many cities. IPO Central+2Moneycontrol+2
- The IPO proceeds aim to support expansion: new stores, store leases, equipment, marketing/advertising and general corporate purposes. IPO Central+2Moneycontrol+2
Financial Snapshot (as per DRHP / IPO-documents)
| Period / Metric | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| Revenue (₹ crore) | ~ 812.62 | ~ 986.35 | ~ 1,273.69 IPO Central+1 |
| Net Income (PAT) | – ₹145.68 cr (loss) | – ₹15.05 cr | – ₹35.00 cr IPO Central+1 |
| EBITDA Margin (%) | Negative in FY23, 6-7% in FY24, ~7.1% in FY25 IPO Central+2IPOInspect+2 | ||
| Net Worth / NAV (₹ per share) | ~ ₹19.48 (FY23) → ~ ₹16.96 (FY25) IPO Central+1 | ||
| ROE / RoNW (%) | Negative (loss-making) in recent years — e.g. –6.72% latest reported IPO Central+1 |
What this means in short: Wakefit has seen solid top-line growth (strong revenue increase), but profitability remains a challenge — losses over last few years. Still, improved margins (EBITDA turning positive) and a clear expansion plan may attract investors with long-term horizon.
GMP (Grey Market Premium) — What the Buzz Says
For those new: Grey Market Premium (GMP) refers to the unofficial premium investors pay in grey-market for IPO shares before they are officially listed. It’s an informal gauge of listing-day demand and sentiment. cleartax+1
Wakefit IPO — GMP Snapshot (as on 3-Dec-2025)
| Date | IPO Price (Upper Band) | GMP (₹/share) | Estimated Listing Price* | Potential Gain %* |
|---|---|---|---|---|
| 03-Dec-2025 | ₹195 | ₹36 Investor Gain+1 | ~ ₹231 | ~ 18.5% |
*Estimated listing price = IPO price + GMP. Gains shown per share assuming IPO allotment.
Interpretation: A ₹36 GMP suggests decent grey-market optimism: if conditions remain stable, Wakefit IPO could list up nearly ~18–20% above upper band — but remember: GMP is unofficial and volatile. Investor Gain+2Goodreturns+2
✋ Caution note: As per experts and IPO-tracking sites, GMP alone should not drive investment decisions — especially for a company with recent losses and profitability turnaround still underway. Investor Gain+2IPOInspect+2
What to Watch & Risk Factors
- Profitability & Margin Pressure: Despite growing revenue, Wakefit hasn’t delivered consistent PAT. Net losses in FY23–25 highlight the risk. Recovery depends on volume growth + controlling costs/expenses.
- Execution Risk: IPO proceeds aim to expand stores and offline presence. If that roll-out or marketing strategy fails, growth expectations might disappoint.
- Valuation vs. Peers: Compared with listed peers (e.g. established mattress/home-furnishing firms), Wakefit may appear risky due to weaker balance sheet / lower NAV per share. IPO Central+1
- GMP volatility: Grey-market indicators are unregulated and can swing wildly. A high GMP today doesn’t guarantee a listing pop tomorrow. Investors relying solely on GMP may get burnt.
My Suggestion
Listen — Wakefit Innovations has the hype: rapid growth, D2C brand appeal, expansion plans. The GMP suggests there’s some buzz building. But on the real fundamentals, the company is walking a tightrope — revenue growing, margins improving, but net profits still shaky.
If you are a short-term trader, you may ride the GMP-induced pop (if listing goes well). But if you are a long-term investor, treat this IPO like a bet: high risk, potentially high reward — only worth it if you believe Wakefit can turn around profitability and scale up sustainably over 2–3 years.
Other IPO’s: Wakefit Innovations IPO
Cardinal Infrastructure Group Inc. (CDNL) IPO – GMP, Price Band, Date & Complete Details